Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
出版年份 2021 全文链接
标题
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
作者
关键词
-
出版物
CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-07-27
DOI
10.1002/cncr.33809
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
- (2020) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
- (2020) Ajay K. Nooka et al. JOURNAL OF CLINICAL ONCOLOGY
- DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Extramedullary Disease in Multiple Myeloma
- (2020) Megan H. Jagosky et al. Current Hematologic Malignancy Reports
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
- (2020) Paul G. Richardson et al. Blood Cancer Journal
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction
- (2019) Muhammad Asad Fraz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function
- (2019) Jin Chen et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Katja Weisel et al. BLOOD
- Treatment Options for Triple-class Refractory Multiple Myeloma
- (2019) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
- (2016) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
- (2016) Rimda Wanchoo et al. Clinical Journal of the American Society of Nephrology
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
- (2013) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now